Public Health – Prostate–Specific Antigen Testing (Protect Our Prostate Act)
The bill outlines specific responsibilities for clinical laboratories regarding the administration of PSA tests. It requires that laboratories use FDA-approved testing assays, adhere to internationally recognized calibration standards, and report test results in a standardized manner. Moreover, laboratories must document and disclose critical information such as the test methodology and assay details to providers. These stipulations aim to enhance the reliability and competency of testing practices while ensuring patient safety through informed decision-making.
Senate Bill 78, also known as the Protect Our Prostate Act, is aimed at enhancing patient care and safety regarding prostate-specific antigen (PSA) testing in Maryland. This legislation mandates that healthcare providers and clinical laboratories must provide essential written information to patients undergoing PSA testing, which is vital for diagnosing prostate disorders. The bill seeks to ensure that patients are well-informed about preparation for testing, potential abnormalities in test results, and the related implications such as the risk of unnecessary treatments due to false positives.
Proponents of SB78 argue that the increased transparency and standardization will lead to better patient outcomes and potentially reduce the incidence of overtreatment stemming from misleading test results. However, there could be challenges in implementation, especially regarding the costs associated with compliance for smaller laboratories. Detractors may highlight concerns about the burden these requirements could place on clinical operations, particularly affecting resource allocation in smaller health facilities struggling to meet new regulatory standards.